Drug Profile
Fasudil - Asahi Kasei/Woolsey Pharmaceuticals
Alternative Names: AT 877; BRAVYL® ; Chuanwei; Eril; Eril Injection; HA 1077; WP-0512Latest Information Update: 18 Jul 2022
Price :
$50
*
At a glance
- Originator Asahi Kasei
- Developer Asahi Kasei; Asahi Kasei Pharma Corp; Eisai Co Ltd; Tianjin Chase Sun Pharmaceutical; Woolsey Pharmaceuticals
- Class Amines; Anti-ischaemics; Ischaemic heart disorder therapies; Isoquinolines; Small molecules; Sulfonamides
- Mechanism of Action Calcium channel antagonists; Protein kinase C inhibitors; Rho-associated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cerebral ischaemia; Cerebral vasospasm
- Phase II Amyotrophic lateral sclerosis; Corticobasal degeneration; Dementia; Progressive supranuclear palsy
- No development reported Pulmonary arterial hypertension
- Discontinued Angina pectoris; Atherosclerosis; HIV-1 infections; Intracranial thrombosis
Most Recent Events
- 11 Feb 2022 Woolsey Pharmaceuticals completed the phase IIa FOUND trial in Dementia (In adults, In the elderly) in USA and Australia (PO) (NCT04793659)
- 22 Dec 2021 Phase-II clinical trials in Amyotrophic lateral sclerosis (In adults, In the elderly) in USA (PO) (NCT05218668)
- 18 Feb 2021 Fasudil - Asahi Kasei/Woolsey Pharmaceuticals receives Orphan Drug status for Corticobasal degeneration in USA